Anti Tau Therapeutics is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Anti-Tau Therapeutics | |
|---|---|
| Category | Disease-Modifying Therapy |
| Target Diseases | Alzheimer's Disease, Progressive Supranuclear Palsy, Corticobasal Degeneration, Primary Tauopathies |
| Mechanism | Reduce tau phosphorylation, aggregation, and propagation |
| Approaches | Kinase inhibitors, aggregation inhibitors, immunotherapy, microtubule stabilizers |
Anti-tau therapeutics aim to modify the course of tauopathies by targeting the pathological accumulation and spread of hyperphosphorylated tau protein. Tau normally stabilizes microtubules, but in disease states it becomes hyperphosphorylated, dissociates from microtubules, aggregates into neurofibrillary tangles (NFTs), and spreads between neurons in a prion-like manner. These therapies represent the most advanced disease-modifying approaches for Alzheimer's disease and primary tauopathies[1].
GSK-3β is the primary kinase responsible for pathological tau phosphorylation.
Critical for normal tau phosphorylation; hyperactivation contributes to pathology.
Tau loss-of-function leads to microtubule destabilization.
AADvac1 (Axon Neuroscience)
ACI-35 (AC Immune)
Lecanemab (BAN2401) (Eisai/Biogen)
Donanemab (LY3002813) (Eli Lilly)
Anti-tau antibodies in development:
| Drug | Company | Mechanism | Phase | Indication |
|---|---|---|---|---|
| Lecanemab | Eisai/Biogen | mAb (Aβ/tau) | III/Approved | Early AD |
| Donanemab | Eli Lilly | mAb (N-tau) | III/Approved | Early AD |
| AADvac1 | Axon | Vaccine | II | AD/PSP |
| Semorinemab | Roche | mAb (mid-domain) | II | AD (failed) |
| Tideglusib | Noscira | GSK-3 inhibitor | II | PSP (failed) |
The study of Anti Tau Therapeutics has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Wang Y, Mandelkow E. Tau in physiology and pathology. Nature Reviews Neuroscience. 2016;17(1):5-21. ↩︎
Forlenza OV, Radanovic M, Talib LL, et al. Lithium and dementia: a systematic review and meta-analysis. Archives of Clinical Neuropsychology. 2019;34(5):677-686. ↩︎
Tolosa E, Litvan I, Höglinger GU, et al. A Phase II trial of tideglusib in PSP. Mov Disord. 2014;29(4):470-478. ↩︎
Wischik CM, Staff RT, Aberg KA, et al. Tau aggregation inhibitor therapy: an exploratory Phase 2 study. J Alzheimers Dis. 2015;43(2):575-588. ↩︎
Zhang B, Carroll J, Trojanowski JQ, et al. The microtubule stabilizer Epothilone D reduces tau-mediated neurodegeneration. Nature Medicine. 2012;18(10):1553-1559. ↩︎
Muresanu V, Buzoianu A, Marschall T, et al. Davunetide for the treatment of mild cognitive impairment. Journal of Alzheimer's Disease. 2016;51(4):1249-1255. ↩︎
Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurology. 2017;16(2):123-134. ↩︎
Novak P, Kovacech B, Katina S, et al. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nature Aging. 2023;3(2):174-187. ↩︎
Theunis C, Crespo-Biel N, Gafner V, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 2013;8(8):e72301. ↩︎
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023;388(1):9-21. ↩︎
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early Alzheimer's disease. JAMA. 2023;329(7):572-582. ↩︎
Xia CF, Arteaga J, Chen G, et al. [^18F]Flortaucipir (AV-1451) binds to tau pathology in AD brain. Nature Medicine. 2017;23(6):765-767. ↩︎
Zetterberg H. Tau in cerebrospinal fluid: a classic biomarker with new applications. Journal of Alzheimer's Disease. 2019;71(2):447-449. ↩︎
Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminatory accuracy of plasma p-tau217 for Alzheimer disease. JAMA Neurol. 2020;77(9):1-10. ↩︎